Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Olema Pharmaceuticals, Inc.
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
25 mars 2025 16h31 HE
|
Olema Oncology
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, at the 2025 AACR Annual Meeting
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
18 mars 2025 16h01 HE
|
Olema Oncology
Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026Pivotal Phase 3 OPERA-02 trial of palazestrant in...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mars 2025 16h30 HE
|
Olema Oncology
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
19 févr. 2025 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
18 févr. 2025 07h00 HE
|
Olema Oncology
SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 févr. 2025 16h30 HE
|
Olema Oncology
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Participate in Upcoming Investor Conferences
03 févr. 2025 16h30 HE
|
Olema Oncology
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 janv. 2025 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
02 janv. 2025 07h00 HE
|
Olema Oncology
SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
10 déc. 2024 07h00 HE
|
Olema Oncology
Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with...